enGene, Inc.

29 articles with enGene, Inc.

• enGene Announces First-in-Human Dosing of EG-70 for the Treatment of Non-Muscle Invasive Bladder Cancer in Phase 1/2 Clinical Trial

  5/27/2021

  enGene Inc., a clinical-stage biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, today announced the dosing of the first patient in the LEGEND study, a first-in-human Phase 1/2 clinical trial of EG-70 in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

• enGene Receives Fast Track Designation for EG-70 for the Treatment of Non-Muscle Invasive Bladder Cancer

  12/3/2020

  enGene   Inc.,   a biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to enGene for EG-70,

• enGene Announces FDA Clearance of IND Application for EG-70, an intravesical dual-immune modulator for the treatment of non-muscle invasive bladder cancer

  11/2/2020

  enGene Inc. announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for EG-70, a first-in-class non-viral gene therapy for the expression of innate and adaptive immune system activators circumscribed to the bladder.

• enGene Receives Funding Through Cystic Fibrosis Foundation's Path to a Cure for the Discovery of Novel Gene Therapies to Treat Cystic Fibrosis

  10/29/2020

  enGene Inc., a biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, announced today an award from the Cystic Fibrosis Foundation for the discovery of genetic medicines to treat patients with cystic fibrosis (CF).

• enGene Appoints José M. Lora, PhD as Chief Scientific Officer

  5/29/2019

  enGene Inc. announced the appointment of José M. Lora, PhD, as Chief Scientific Officer.

• 

  New CEOs Named in BioSpace’s Biopharma Movers and Shakers for July 23

  7/23/2018

  It’s been a busy week for biopharma companies to name a chief executive officer. Over the past week, multiple companies have selected individuals to hold the top spots and guide the growth strategies of their companies.

• enGene Appoints Veteran Life Sciences Executive Jason D. Hanson as Chief Executive Officer and President

  7/16/2018

  enGene Inc. announced the appointment of Jason D. Hanson as President, Chief Executive Officer and Director.

• Industry Veteran Mr. Steve Gannon Joins enGene's Board of Directors

  7/10/2017

• enGene Announces Appointment Of Theresa Podrebarac, MD, As Chief Medical Officer

  5/1/2017

• enGene, Inc.'s Mucosal Gene Delivery Platform Is Successful In Targeting PD-L1 Expression In The Gut, Demonstrating Effective Treatment Of Colitis And Gvhd In Preclinical Models

  4/28/2017

• Takeda And enGene, Inc. Establish Strategic Alliance To Develop Novel Therapeutics For Gastrointestinal Diseases

  1/12/2016

• enGene, Inc. Annouces The Appointment Of Dr. Dennis H. Langer To The Company's Board Of Directors

  12/8/2015

• enGene, Inc., Johnson & Johnson Ink Inflammatory Bowel Disease Pact for C $441 Million

  10/14/2015

• Forbion Capital Partners Leads CAD 13.5 Million (EUR 9.6 Million) Series B Financing Round For enGene, Inc.

  1/26/2015

• Lumira Capital Announces Investment in enGene, Inc.

  8/5/2013

• enGene, Inc. CSO to Present Key Pre-Clinical Data on EG-10 for Treating Inflammatory Bowel Disease

  12/6/2010

• enGene, Inc. Adds Leading Nanomedicine Expert To Scientific Advisory Board

  9/2/2010

• enGene, Inc. to Present Research Data on EG-10 for Inflammatory Bowel Disease (IBD)

  2/25/2010

• enGene, Inc. CEO to Present at Rodman & Renshaw Healthcare Conference

  8/11/2009

• enGene, Inc. Receives NRC-IRAP Contribution, Initiates Convertible Note Financing

  6/11/2009